在眼部炎症的HumiraTaper (HOT) 研究
Francesco Pichi1, Scott D Smith1, Debra A Goldstein2
1From the Eye Institute (F.P., S.D.S., A.A., P.N.), Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates; Cleveland Clinic Lerner College of Medicine (F.P., S.D.S., A.A., P.N.), Case Western Reserve University , Cleveland, Ohio, USA.
American journal of ophthalmology
|September 21, 2023
概括
年龄较小,阿达利穆马布的缓解速度较快,缓解期较短增加非传染性紫外炎复发风险. 建议缓慢降低剂量和更长的缓解期适用于接受阿达利木马布逐渐减缓治疗的患者.
科学领域:
- 眼科医生 眼科 眼科
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
背景情况:
- 非传染性眼膜炎 (NIU) 是一种慢性炎症性眼病.
- 阿达利穆马布是一种常见的生物疗法,用于在NIU中实现缓解.
- 减少阿达利穆马布的使用需要仔细考虑,以防止疾病复发.
研究的目的:
- 为了确定影响非传染性紫外炎患者在阿达利穆马布剂量减少后复发风险的因素.
- 评估患者人口统计学和治疗参数对膜炎复发在阿达利穆马布逐渐减少后的影响.
主要方法:
- 这是一项回顾性多中心研究,涉及328名NIU患者,接受了Adalimumab治疗.
- 收集的数据包括患者人口统计学,NIU类型,病史,缓解持续时间和阿达利木马布逐渐减缓时间表.
- 统计分析确定了脑膜炎复发率的预测因素.
主要成果:
- 在39.6%的患者中观察到复发,较年轻的患者 (平均年龄为29.4岁) 患病率更高.
- 较快的阿达利穆马布逐渐减少时间表与复发风险增加显著相关 (HR=1.23).
- 在逐渐减少之前,较长时间的不活动 (平均100.8周) 与较低的复发率 (HR=0.97) 有关.
结论:
- 患者的年龄,种族和阿达利穆马布缓解的持续时间是剂量逐渐减少的关键因素.
- 建议采用慢慢逐步减少阿达利穆马布的治疗策略,以最大限度地减少非传染性脑膜炎复发.
- 考虑到个体患者因素的个性化逐渐缩减协议可能会改善长期的结果.
相关概念视频
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
289
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
289
01:27Open Angle Glaucoma: Treatment
474
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
474
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
186
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
186
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
144
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
144
01:28Angle Closure Glaucoma: Treatment
555
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
555
01:29Inflammatory Bowel Disease IV: Pharmacological Management
145
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
145